A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy

NCT00074854 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
87
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer